| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 301 | 2024 | 2571 | 22.550 |
Why?
|
| Venous Thromboembolism | 145 | 2024 | 1869 | 15.670 |
Why?
|
| Anticoagulants | 274 | 2024 | 4795 | 14.890 |
Why?
|
| Venous Thrombosis | 133 | 2024 | 1304 | 13.040 |
Why?
|
| Fibrinolytic Agents | 88 | 2024 | 2075 | 6.830 |
Why?
|
| Thrombolytic Therapy | 108 | 2024 | 2055 | 6.720 |
Why?
|
| Warfarin | 67 | 2021 | 1482 | 6.550 |
Why?
|
| Thromboembolism | 54 | 2024 | 992 | 5.110 |
Why?
|
| Enoxaparin | 33 | 2022 | 391 | 4.890 |
Why?
|
| Heparin | 61 | 2023 | 1632 | 4.120 |
Why?
|
| Tissue Plasminogen Activator | 52 | 2024 | 1162 | 4.100 |
Why?
|
| Atrial Fibrillation | 55 | 2024 | 5114 | 4.010 |
Why?
|
| Hemorrhage | 98 | 2024 | 3422 | 3.370 |
Why?
|
| Heparin, Low-Molecular-Weight | 35 | 2023 | 344 | 3.350 |
Why?
|
| Benzamides | 22 | 2021 | 1371 | 3.060 |
Why?
|
| Vena Cava Filters | 23 | 2019 | 261 | 2.900 |
Why?
|
| Thrombophlebitis | 36 | 2004 | 289 | 2.700 |
Why?
|
| Stroke | 51 | 2023 | 9721 | 2.540 |
Why?
|
| Acute Disease | 87 | 2024 | 7226 | 2.530 |
Why?
|
| Pyridines | 29 | 2021 | 2872 | 2.480 |
Why?
|
| Antithrombins | 10 | 2021 | 294 | 2.290 |
Why?
|
| Thrombosis | 34 | 2024 | 2944 | 2.160 |
Why?
|
| Blood Coagulation | 16 | 2021 | 1156 | 2.090 |
Why?
|
| Postthrombotic Syndrome | 10 | 2021 | 28 | 1.950 |
Why?
|
| Registries | 70 | 2024 | 8246 | 1.940 |
Why?
|
| Risk Factors | 212 | 2024 | 74241 | 1.890 |
Why?
|
| Inpatients | 21 | 2020 | 2545 | 1.870 |
Why?
|
| Ventricular Dysfunction, Right | 27 | 2022 | 629 | 1.790 |
Why?
|
| Embolism | 5 | 2023 | 399 | 1.700 |
Why?
|
| Humans | 683 | 2024 | 761222 | 1.650 |
Why?
|
| Hospitalization | 50 | 2024 | 10707 | 1.640 |
Why?
|
| Embolectomy | 15 | 2021 | 130 | 1.610 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 22 | 2018 | 425 | 1.470 |
Why?
|
| Vitamin K | 13 | 2024 | 313 | 1.460 |
Why?
|
| International Normalized Ratio | 22 | 2020 | 382 | 1.420 |
Why?
|
| beta-Alanine | 6 | 2014 | 82 | 1.400 |
Why?
|
| Aged | 271 | 2024 | 169292 | 1.370 |
Why?
|
| Pyridones | 9 | 2021 | 809 | 1.320 |
Why?
|
| Thrombophilia | 13 | 2020 | 306 | 1.300 |
Why?
|
| Myocardial Infarction | 40 | 2024 | 11476 | 1.240 |
Why?
|
| Ventricular Function, Right | 6 | 2020 | 618 | 1.160 |
Why?
|
| Risk Assessment | 83 | 2024 | 24022 | 1.160 |
Why?
|
| Middle Aged | 279 | 2024 | 220858 | 1.130 |
Why?
|
| Female | 334 | 2024 | 392552 | 1.130 |
Why?
|
| Treatment Outcome | 124 | 2024 | 64681 | 1.130 |
Why?
|
| Male | 323 | 2024 | 360703 | 1.110 |
Why?
|
| Leg | 16 | 2015 | 1087 | 1.070 |
Why?
|
| Pulmonary Medicine | 2 | 2019 | 221 | 1.050 |
Why?
|
| Benzimidazoles | 7 | 2014 | 858 | 1.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 23 | 1999 | 325 | 1.030 |
Why?
|
| Hospital Costs | 8 | 2019 | 947 | 1.000 |
Why?
|
| Platelet Aggregation Inhibitors | 20 | 2023 | 2746 | 0.990 |
Why?
|
| Time Factors | 77 | 2021 | 39957 | 0.970 |
Why?
|
| Administration, Oral | 30 | 2024 | 4015 | 0.960 |
Why?
|
| Cardiology | 9 | 2021 | 1693 | 0.960 |
Why?
|
| Pulmonary Artery | 16 | 2021 | 1929 | 0.950 |
Why?
|
| Medical Order Entry Systems | 4 | 2013 | 521 | 0.940 |
Why?
|
| Pyrazoles | 9 | 2021 | 2010 | 0.930 |
Why?
|
| Outpatients | 7 | 2024 | 1598 | 0.860 |
Why?
|
| Iliac Vein | 6 | 2021 | 70 | 0.860 |
Why?
|
| Plasminogen Activators | 10 | 2009 | 199 | 0.850 |
Why?
|
| Drug Administration Schedule | 33 | 2021 | 4851 | 0.840 |
Why?
|
| Decision Support Systems, Clinical | 6 | 2011 | 1172 | 0.840 |
Why?
|
| Thrombocytopenia | 7 | 2021 | 1182 | 0.820 |
Why?
|
| Venous Insufficiency | 3 | 2018 | 108 | 0.820 |
Why?
|
| Aged, 80 and over | 92 | 2021 | 58952 | 0.810 |
Why?
|
| Ultrasonic Therapy | 3 | 2020 | 215 | 0.800 |
Why?
|
| Randomized Controlled Trials as Topic | 40 | 2024 | 10218 | 0.780 |
Why?
|
| Adult | 191 | 2024 | 221120 | 0.740 |
Why?
|
| Thrombectomy | 9 | 2012 | 703 | 0.740 |
Why?
|
| Aircraft | 3 | 2011 | 130 | 0.740 |
Why?
|
| Catheters | 6 | 2024 | 426 | 0.740 |
Why?
|
| Guideline Adherence | 13 | 2022 | 2220 | 0.730 |
Why?
|
| Hypertension, Pulmonary | 8 | 2019 | 1592 | 0.730 |
Why?
|
| Premedication | 8 | 2019 | 246 | 0.730 |
Why?
|
| Renal Insufficiency | 3 | 2023 | 808 | 0.720 |
Why?
|
| Catheterization, Peripheral | 7 | 2019 | 343 | 0.720 |
Why?
|
| Recurrence | 32 | 2022 | 8457 | 0.700 |
Why?
|
| Aspirin | 21 | 2023 | 3129 | 0.700 |
Why?
|
| Drug Utilization Review | 2 | 2014 | 248 | 0.700 |
Why?
|
| Prospective Studies | 92 | 2024 | 54437 | 0.700 |
Why?
|
| Glycosaminoglycans | 3 | 2020 | 607 | 0.690 |
Why?
|
| Ultrasonography | 34 | 2019 | 5969 | 0.690 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2020 | 1812 | 0.680 |
Why?
|
| Drug Therapy, Computer-Assisted | 4 | 2020 | 197 | 0.680 |
Why?
|
| Tomography, X-Ray Computed | 34 | 2019 | 20588 | 0.670 |
Why?
|
| Heart Failure | 19 | 2024 | 11701 | 0.670 |
Why?
|
| Catheterization, Central Venous | 6 | 2019 | 526 | 0.670 |
Why?
|
| Medication Errors | 5 | 2023 | 783 | 0.670 |
Why?
|
| Patient Discharge | 11 | 2021 | 3441 | 0.660 |
Why?
|
| Femoral Vein | 5 | 2020 | 153 | 0.660 |
Why?
|
| Neoplasms | 35 | 2024 | 22142 | 0.640 |
Why?
|
| Kidney Function Tests | 1 | 2021 | 680 | 0.630 |
Why?
|
| Echocardiography | 19 | 2021 | 5006 | 0.620 |
Why?
|
| Dalteparin | 6 | 2015 | 44 | 0.610 |
Why?
|
| Varicose Ulcer | 1 | 2018 | 55 | 0.610 |
Why?
|
| Blood Coagulation Tests | 2 | 2019 | 271 | 0.610 |
Why?
|
| Aortic Rupture | 1 | 2021 | 319 | 0.600 |
Why?
|
| Preventive Health Services | 2 | 2015 | 567 | 0.600 |
Why?
|
| Intracranial Hemorrhages | 4 | 2019 | 809 | 0.590 |
Why?
|
| Hypoalbuminemia | 1 | 2018 | 86 | 0.590 |
Why?
|
| Coronary Artery Bypass | 9 | 2010 | 2193 | 0.580 |
Why?
|
| Ultrasonography, Interventional | 4 | 2020 | 1496 | 0.580 |
Why?
|
| Thiazoles | 5 | 2020 | 1517 | 0.570 |
Why?
|
| Polysaccharides | 8 | 2015 | 1014 | 0.570 |
Why?
|
| Comorbidity | 26 | 2024 | 10516 | 0.570 |
Why?
|
| Stockings, Compression | 5 | 2019 | 36 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 17 | 2020 | 7400 | 0.560 |
Why?
|
| United States | 73 | 2024 | 72341 | 0.560 |
Why?
|
| Phlebography | 10 | 2020 | 326 | 0.560 |
Why?
|
| Syncope | 2 | 2019 | 428 | 0.560 |
Why?
|
| Veins | 4 | 2018 | 767 | 0.560 |
Why?
|
| Hypertrophy, Right Ventricular | 4 | 2015 | 109 | 0.540 |
Why?
|
| Hematoma | 1 | 2021 | 763 | 0.530 |
Why?
|
| Fibrinolysis | 6 | 2019 | 332 | 0.530 |
Why?
|
| Immobilization | 11 | 2020 | 229 | 0.530 |
Why?
|
| Social Class | 2 | 2024 | 1993 | 0.520 |
Why?
|
| Medication Adherence | 7 | 2020 | 2175 | 0.520 |
Why?
|
| Infusions, Intravenous | 16 | 2015 | 2217 | 0.500 |
Why?
|
| Double-Blind Method | 38 | 2023 | 12341 | 0.490 |
Why?
|
| Morpholines | 4 | 2014 | 581 | 0.480 |
Why?
|
| Pharmacists | 2 | 2014 | 259 | 0.480 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 244 | 0.480 |
Why?
|
| Predictive Value of Tests | 32 | 2023 | 15308 | 0.480 |
Why?
|
| Angiography | 16 | 2019 | 1597 | 0.470 |
Why?
|
| Bandages | 7 | 2005 | 269 | 0.470 |
Why?
|
| Angina Pectoris | 7 | 2016 | 959 | 0.470 |
Why?
|
| Heart Ventricles | 7 | 2021 | 3813 | 0.460 |
Why?
|
| Arterial Occlusive Diseases | 4 | 2016 | 749 | 0.460 |
Why?
|
| Women | 1 | 2016 | 224 | 0.460 |
Why?
|
| Thiophenes | 4 | 2014 | 569 | 0.450 |
Why?
|
| Platelet Factor 4 | 2 | 2011 | 129 | 0.440 |
Why?
|
| Quality of Life | 13 | 2024 | 13367 | 0.440 |
Why?
|
| Europe | 7 | 2020 | 3423 | 0.440 |
Why?
|
| Pharmaceutical Preparations | 2 | 2022 | 1086 | 0.440 |
Why?
|
| Gastrointestinal Diseases | 3 | 2024 | 1201 | 0.440 |
Why?
|
| Length of Stay | 16 | 2021 | 6417 | 0.440 |
Why?
|
| Secondary Prevention | 13 | 2018 | 1472 | 0.440 |
Why?
|
| Severity of Illness Index | 21 | 2021 | 15841 | 0.440 |
Why?
|
| Coronary Thrombosis | 4 | 2012 | 440 | 0.440 |
Why?
|
| Popliteal Vein | 3 | 2020 | 43 | 0.430 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 1305 | 0.430 |
Why?
|
| Lower Extremity | 4 | 2019 | 1201 | 0.430 |
Why?
|
| Postoperative Complications | 24 | 2022 | 15637 | 0.430 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2021 | 1462 | 0.430 |
Why?
|
| Streptokinase | 12 | 2001 | 186 | 0.430 |
Why?
|
| Prognosis | 34 | 2021 | 29688 | 0.430 |
Why?
|
| Incidence | 38 | 2024 | 21366 | 0.420 |
Why?
|
| Ticlopidine | 5 | 2010 | 730 | 0.420 |
Why?
|
| Catheterization | 8 | 2019 | 1428 | 0.420 |
Why?
|
| Legislation, Drug | 1 | 2015 | 214 | 0.420 |
Why?
|
| Wounds and Injuries | 3 | 2020 | 2493 | 0.420 |
Why?
|
| Risk | 23 | 2019 | 9616 | 0.420 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 1270 | 0.410 |
Why?
|
| Clinical Trials as Topic | 34 | 2020 | 8002 | 0.410 |
Why?
|
| Patient Education as Topic | 4 | 2012 | 2317 | 0.410 |
Why?
|
| Anemia | 2 | 2021 | 1504 | 0.400 |
Why?
|
| Hospital Mortality | 8 | 2021 | 5295 | 0.400 |
Why?
|
| Chemoprevention | 3 | 2023 | 325 | 0.400 |
Why?
|
| Hospitals, University | 2 | 2011 | 565 | 0.390 |
Why?
|
| Follow-Up Studies | 44 | 2021 | 39127 | 0.390 |
Why?
|
| Cardiovascular Diseases | 20 | 2024 | 15521 | 0.390 |
Why?
|
| Preoperative Care | 2 | 2012 | 2241 | 0.380 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 830 | 0.380 |
Why?
|
| Tomography, Spiral Computed | 5 | 2005 | 273 | 0.380 |
Why?
|
| Reminder Systems | 4 | 2009 | 386 | 0.370 |
Why?
|
| Recombinant Proteins | 26 | 2017 | 6504 | 0.370 |
Why?
|
| Oral Hemorrhage | 1 | 2010 | 24 | 0.370 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2020 | 2254 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2021 | 10756 | 0.370 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 1067 | 0.370 |
Why?
|
| Intermittent Pneumatic Compression Devices | 3 | 2010 | 28 | 0.360 |
Why?
|
| Vena Cava, Inferior | 7 | 2024 | 459 | 0.360 |
Why?
|
| Advance Directive Adherence | 1 | 2010 | 19 | 0.360 |
Why?
|
| Blood Coagulation Disorders | 2 | 2012 | 350 | 0.360 |
Why?
|
| Embolism, Paradoxical | 1 | 2010 | 54 | 0.350 |
Why?
|
| Drug Substitution | 1 | 2013 | 291 | 0.350 |
Why?
|
| Patient Readmission | 3 | 2021 | 3265 | 0.350 |
Why?
|
| Endarterectomy | 1 | 2011 | 196 | 0.350 |
Why?
|
| Age Factors | 19 | 2021 | 18384 | 0.350 |
Why?
|
| Ginkgo biloba | 1 | 2010 | 26 | 0.350 |
Why?
|
| Obesity | 11 | 2023 | 12940 | 0.340 |
Why?
|
| Education, Medical, Continuing | 2 | 2013 | 825 | 0.340 |
Why?
|
| Intensive Care Units | 9 | 2023 | 3744 | 0.340 |
Why?
|
| Edema | 2 | 2011 | 764 | 0.340 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2015 | 2131 | 0.340 |
Why?
|
| Budgets | 1 | 2011 | 230 | 0.340 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2024 | 1116 | 0.330 |
Why?
|
| Surgical Procedures, Operative | 8 | 2010 | 1923 | 0.330 |
Why?
|
| Tooth Extraction | 1 | 2010 | 227 | 0.330 |
Why?
|
| Multicenter Studies as Topic | 8 | 2021 | 1702 | 0.320 |
Why?
|
| Aortic Aneurysm, Abdominal | 3 | 2023 | 1228 | 0.320 |
Why?
|
| Hospital Information Systems | 2 | 2009 | 394 | 0.320 |
Why?
|
| Cohort Studies | 31 | 2022 | 41496 | 0.320 |
Why?
|
| Acetanilides | 1 | 2010 | 169 | 0.320 |
Why?
|
| Catheter Ablation | 1 | 2022 | 2751 | 0.310 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 3354 | 0.310 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2010 | 4014 | 0.310 |
Why?
|
| Quality Improvement | 2 | 2014 | 3808 | 0.310 |
Why?
|
| Foreign-Body Migration | 1 | 2010 | 220 | 0.310 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3093 | 0.310 |
Why?
|
| Cost-Benefit Analysis | 12 | 2019 | 5493 | 0.310 |
Why?
|
| Antifibrinolytic Agents | 4 | 2005 | 287 | 0.310 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3215 | 0.310 |
Why?
|
| Patient Advocacy | 2 | 2009 | 358 | 0.310 |
Why?
|
| Vitamin E | 2 | 2010 | 872 | 0.310 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2010 | 295 | 0.300 |
Why?
|
| Inflammation | 3 | 2020 | 10759 | 0.300 |
Why?
|
| Orchiectomy | 1 | 2010 | 463 | 0.300 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2016 | 278 | 0.300 |
Why?
|
| Physical Examination | 4 | 2009 | 1255 | 0.300 |
Why?
|
| Emergency Service, Hospital | 11 | 2022 | 7865 | 0.300 |
Why?
|
| Medical History Taking | 2 | 2009 | 773 | 0.300 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2011 | 494 | 0.300 |
Why?
|
| Capsule Endoscopy | 1 | 2008 | 102 | 0.290 |
Why?
|
| Troponin | 4 | 2014 | 504 | 0.290 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 1275 | 0.290 |
Why?
|
| Proportional Hazards Models | 20 | 2021 | 12474 | 0.290 |
Why?
|
| C-Reactive Protein | 4 | 2018 | 3821 | 0.290 |
Why?
|
| Phytotherapy | 1 | 2010 | 296 | 0.290 |
Why?
|
| Medication Systems, Hospital | 2 | 2007 | 154 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2021 | 6486 | 0.290 |
Why?
|
| Myocardial Revascularization | 1 | 2011 | 794 | 0.290 |
Why?
|
| Coronary Restenosis | 1 | 2010 | 396 | 0.290 |
Why?
|
| Transaminases | 2 | 2018 | 199 | 0.290 |
Why?
|
| Pelvis | 3 | 2015 | 735 | 0.280 |
Why?
|
| Injections, Subcutaneous | 8 | 2015 | 672 | 0.280 |
Why?
|
| Drug Monitoring | 4 | 2020 | 961 | 0.280 |
Why?
|
| Travel | 3 | 2010 | 796 | 0.280 |
Why?
|
| Magnetic Resonance Angiography | 5 | 2016 | 1432 | 0.280 |
Why?
|
| Pigmentation Disorders | 1 | 2007 | 104 | 0.270 |
Why?
|
| Electrocardiography | 14 | 2016 | 6387 | 0.270 |
Why?
|
| Bleeding Time | 3 | 1991 | 83 | 0.270 |
Why?
|
| Radiography | 19 | 2016 | 6974 | 0.270 |
Why?
|
| Cardiovascular Agents | 2 | 2010 | 842 | 0.270 |
Why?
|
| Research Design | 13 | 2017 | 6180 | 0.270 |
Why?
|
| Pipecolic Acids | 1 | 2007 | 77 | 0.270 |
Why?
|
| Diagnosis, Differential | 14 | 2012 | 12976 | 0.270 |
Why?
|
| Cause of Death | 12 | 2020 | 3688 | 0.270 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2005 | 513 | 0.270 |
Why?
|
| Toes | 1 | 2007 | 209 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 1413 | 0.260 |
Why?
|
| Aftercare | 3 | 2021 | 913 | 0.260 |
Why?
|
| Craniotomy | 2 | 2002 | 741 | 0.260 |
Why?
|
| Drug Prescriptions | 4 | 2020 | 1668 | 0.260 |
Why?
|
| Catheterization, Swan-Ganz | 2 | 2017 | 86 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2022 | 1394 | 0.260 |
Why?
|
| Lung | 13 | 2010 | 9979 | 0.260 |
Why?
|
| Partial Thromboplastin Time | 6 | 2019 | 204 | 0.260 |
Why?
|
| Hirudins | 1 | 2007 | 179 | 0.260 |
Why?
|
| Radionuclide Imaging | 15 | 2004 | 1989 | 0.260 |
Why?
|
| Orthopedic Procedures | 3 | 2013 | 1276 | 0.260 |
Why?
|
| Ambulatory Care | 5 | 2019 | 2770 | 0.250 |
Why?
|
| Dementia | 2 | 2018 | 2684 | 0.250 |
Why?
|
| Lipoprotein(a) | 1 | 2010 | 482 | 0.250 |
Why?
|
| Confidence Intervals | 9 | 2018 | 2928 | 0.250 |
Why?
|
| Evidence-Based Medicine | 9 | 2016 | 3691 | 0.250 |
Why?
|
| Thrombin | 3 | 2014 | 593 | 0.250 |
Why?
|
| Models, Statistical | 7 | 2020 | 5081 | 0.250 |
Why?
|
| Medicare | 6 | 2024 | 6774 | 0.250 |
Why?
|
| Coronary Artery Disease | 6 | 2018 | 6506 | 0.250 |
Why?
|
| Hospital Departments | 1 | 2005 | 134 | 0.240 |
Why?
|
| Prosthesis Failure | 1 | 2010 | 1204 | 0.240 |
Why?
|
| Prescriptions | 1 | 2007 | 386 | 0.240 |
Why?
|
| Ischemic Attack, Transient | 2 | 2021 | 874 | 0.240 |
Why?
|
| Chi-Square Distribution | 7 | 2012 | 3418 | 0.240 |
Why?
|
| Retrospective Studies | 36 | 2022 | 80675 | 0.240 |
Why?
|
| Health Status Indicators | 2 | 2016 | 970 | 0.240 |
Why?
|
| Mammography | 1 | 2015 | 2430 | 0.240 |
Why?
|
| Drug Costs | 5 | 2019 | 1183 | 0.240 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2010 | 1724 | 0.230 |
Why?
|
| Residence Characteristics | 2 | 2014 | 2092 | 0.230 |
Why?
|
| Survival Analysis | 13 | 2021 | 10088 | 0.230 |
Why?
|
| Probability | 8 | 2009 | 2478 | 0.230 |
Why?
|
| History, 20th Century | 5 | 2024 | 2765 | 0.230 |
Why?
|
| Prostatic Neoplasms | 6 | 2016 | 11101 | 0.230 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2005 | 131 | 0.230 |
Why?
|
| Survival Rate | 16 | 2021 | 12728 | 0.230 |
Why?
|
| Patient Compliance | 4 | 2019 | 2688 | 0.230 |
Why?
|
| Nephrotic Syndrome | 1 | 2008 | 382 | 0.230 |
Why?
|
| Multivariate Analysis | 13 | 2017 | 12052 | 0.230 |
Why?
|
| Heart Diseases | 6 | 2010 | 2795 | 0.230 |
Why?
|
| Prothrombin Time | 3 | 2020 | 117 | 0.230 |
Why?
|
| ABO Blood-Group System | 2 | 2021 | 381 | 0.230 |
Why?
|
| Critical Illness | 5 | 2020 | 2724 | 0.220 |
Why?
|
| Puerperal Disorders | 2 | 2005 | 301 | 0.220 |
Why?
|
| Patient Selection | 11 | 2020 | 4246 | 0.220 |
Why?
|
| Societies, Medical | 7 | 2018 | 3923 | 0.220 |
Why?
|
| Reproducibility of Results | 18 | 2023 | 20118 | 0.220 |
Why?
|
| Factor V | 5 | 2007 | 168 | 0.220 |
Why?
|
| Platelet Transfusion | 1 | 2006 | 298 | 0.220 |
Why?
|
| Odds Ratio | 12 | 2021 | 9652 | 0.220 |
Why?
|
| Body Mass Index | 11 | 2023 | 12952 | 0.220 |
Why?
|
| Boston | 9 | 2011 | 9327 | 0.220 |
Why?
|
| Infusion Pumps | 2 | 2019 | 163 | 0.210 |
Why?
|
| Anticarcinogenic Agents | 1 | 2005 | 249 | 0.210 |
Why?
|
| Quality Assurance, Health Care | 3 | 2009 | 2164 | 0.210 |
Why?
|
| Arm | 2 | 2004 | 589 | 0.210 |
Why?
|
| Sensitivity and Specificity | 21 | 2012 | 14675 | 0.210 |
Why?
|
| Massachusetts | 11 | 2021 | 8837 | 0.210 |
Why?
|
| Prevalence | 9 | 2021 | 15721 | 0.210 |
Why?
|
| Denmark | 6 | 2021 | 770 | 0.210 |
Why?
|
| Drug Therapy, Combination | 10 | 2020 | 6304 | 0.210 |
Why?
|
| Pregnancy Complications, Hematologic | 3 | 2003 | 180 | 0.210 |
Why?
|
| Bone Density | 1 | 2015 | 3546 | 0.200 |
Why?
|
| Sex Factors | 14 | 2020 | 10553 | 0.200 |
Why?
|
| Memory Disorders | 1 | 2010 | 1198 | 0.200 |
Why?
|
| Macular Degeneration | 1 | 2010 | 1009 | 0.200 |
Why?
|
| Hematologic Agents | 1 | 2002 | 40 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 3245 | 0.200 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2001 | 537 | 0.200 |
Why?
|
| Radiography, Thoracic | 2 | 2009 | 1302 | 0.200 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 1874 | 0.200 |
Why?
|
| Chest Pain | 3 | 2016 | 1097 | 0.200 |
Why?
|
| History, 21st Century | 3 | 2024 | 1567 | 0.200 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 1069 | 0.200 |
Why?
|
| Kidney | 1 | 2017 | 7033 | 0.200 |
Why?
|
| Mitral Valve Prolapse | 4 | 1999 | 212 | 0.200 |
Why?
|
| Drug Interactions | 4 | 2010 | 1417 | 0.200 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2017 | 1725 | 0.200 |
Why?
|
| Infusions, Intra-Arterial | 4 | 2017 | 221 | 0.200 |
Why?
|
| Fibric Acids | 1 | 2021 | 27 | 0.190 |
Why?
|
| Hemodynamics | 10 | 2005 | 4165 | 0.190 |
Why?
|
| Referral and Consultation | 2 | 2020 | 3608 | 0.190 |
Why?
|
| Asia | 2 | 2020 | 622 | 0.190 |
Why?
|
| Adolescent | 32 | 2023 | 88300 | 0.190 |
Why?
|
| Contraceptives, Oral | 3 | 1996 | 554 | 0.190 |
Why?
|
| Hospitals | 6 | 2020 | 3881 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2002 | 3803 | 0.190 |
Why?
|
| Colonoscopy | 1 | 2009 | 1395 | 0.180 |
Why?
|
| Factor X | 2 | 2014 | 64 | 0.180 |
Why?
|
| Triage | 2 | 2006 | 985 | 0.180 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2022 | 165 | 0.180 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 1385 | 0.180 |
Why?
|
| Niacin | 1 | 2021 | 117 | 0.180 |
Why?
|
| Wit and Humor as Topic | 1 | 2000 | 31 | 0.180 |
Why?
|
| Age Distribution | 4 | 2020 | 2871 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2017 | 858 | 0.180 |
Why?
|
| Testosterone | 2 | 2013 | 2472 | 0.180 |
Why?
|
| Cross-Cultural Comparison | 2 | 2002 | 634 | 0.180 |
Why?
|
| Safety | 7 | 2007 | 1151 | 0.180 |
Why?
|
| Peptide Fragments | 2 | 2017 | 5103 | 0.180 |
Why?
|
| Heart | 3 | 2003 | 4431 | 0.180 |
Why?
|
| Health Care Reform | 1 | 2009 | 1247 | 0.170 |
Why?
|
| Heart Valve Prosthesis | 2 | 2006 | 1463 | 0.170 |
Why?
|
| Tamoxifen | 1 | 2005 | 965 | 0.170 |
Why?
|
| Prothrombin | 3 | 2014 | 192 | 0.170 |
Why?
|
| Ultrasonography, Doppler, Duplex | 2 | 2019 | 198 | 0.170 |
Why?
|
| Decision Support Techniques | 4 | 2020 | 2004 | 0.170 |
Why?
|
| Observer Variation | 4 | 2016 | 2610 | 0.170 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2021 | 110 | 0.170 |
Why?
|
| Dyspnea | 5 | 2010 | 1347 | 0.170 |
Why?
|
| Hematologic Tests | 2 | 1992 | 239 | 0.170 |
Why?
|
| Piperazines | 1 | 2010 | 2522 | 0.170 |
Why?
|
| Reperfusion | 1 | 2021 | 271 | 0.170 |
Why?
|
| Coronary Disease | 8 | 2004 | 5921 | 0.170 |
Why?
|
| Shock, Cardiogenic | 3 | 2005 | 709 | 0.170 |
Why?
|
| Mixed Function Oxygenases | 2 | 2011 | 265 | 0.160 |
Why?
|
| Middle East | 1 | 2020 | 231 | 0.160 |
Why?
|
| Recovery of Function | 3 | 2020 | 2981 | 0.160 |
Why?
|
| Device Removal | 2 | 2017 | 629 | 0.160 |
Why?
|
| Biomedical Research | 4 | 2017 | 3434 | 0.160 |
Why?
|
| Blood Pressure | 9 | 2005 | 8479 | 0.160 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2020 | 110 | 0.160 |
Why?
|
| Critical Pathways | 3 | 2020 | 475 | 0.160 |
Why?
|
| Pericardium | 2 | 2002 | 674 | 0.160 |
Why?
|
| Latin America | 1 | 2020 | 412 | 0.160 |
Why?
|
| Aortic Valve Insufficiency | 3 | 1988 | 576 | 0.160 |
Why?
|
| Diagnostic Imaging | 6 | 2012 | 3534 | 0.160 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2021 | 411 | 0.150 |
Why?
|
| Heart Valve Diseases | 2 | 2006 | 1031 | 0.150 |
Why?
|
| Atherosclerosis | 3 | 2023 | 3407 | 0.150 |
Why?
|
| International Cooperation | 4 | 2018 | 1423 | 0.150 |
Why?
|
| Iran | 4 | 2022 | 736 | 0.150 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 4243 | 0.150 |
Why?
|
| Canada | 5 | 2023 | 2125 | 0.150 |
Why?
|
| Selection Bias | 1 | 2020 | 359 | 0.150 |
Why?
|
| Platelet Function Tests | 2 | 1990 | 271 | 0.150 |
Why?
|
| Physicians | 6 | 2013 | 4584 | 0.150 |
Why?
|
| Minnesota | 1 | 2018 | 337 | 0.150 |
Why?
|
| Orthopedics | 2 | 2021 | 898 | 0.150 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 1998 | 832 | 0.150 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2019 | 265 | 0.150 |
Why?
|
| Medical Oncology | 4 | 2024 | 2320 | 0.140 |
Why?
|
| Software | 3 | 2009 | 4431 | 0.140 |
Why?
|
| Perioperative Care | 4 | 2016 | 1037 | 0.140 |
Why?
|
| Health Promotion | 1 | 2009 | 2205 | 0.140 |
Why?
|
| Consensus | 3 | 2023 | 3134 | 0.140 |
Why?
|
| ROC Curve | 6 | 2017 | 3584 | 0.140 |
Why?
|
| Statistics, Nonparametric | 4 | 2018 | 2854 | 0.140 |
Why?
|
| Emergencies | 3 | 2021 | 1217 | 0.140 |
Why?
|
| Diabetic Nephropathies | 4 | 2005 | 973 | 0.140 |
Why?
|
| Risk Adjustment | 1 | 2021 | 601 | 0.140 |
Why?
|
| Fibrinogen | 6 | 2009 | 888 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2012 | 3201 | 0.140 |
Why?
|
| Intention to Treat Analysis | 5 | 2017 | 413 | 0.140 |
Why?
|
| Pregnancy Complications | 2 | 2010 | 2949 | 0.140 |
Why?
|
| Biphenyl Compounds | 4 | 2006 | 1007 | 0.140 |
Why?
|
| Hypertension | 9 | 2020 | 8536 | 0.140 |
Why?
|
| Pregnancy | 16 | 2024 | 29893 | 0.140 |
Why?
|
| Young Adult | 15 | 2022 | 59222 | 0.140 |
Why?
|
| Critical Care | 4 | 2021 | 2696 | 0.140 |
Why?
|
| Pandemics | 6 | 2022 | 8663 | 0.130 |
Why?
|
| Epinephrine | 1 | 2000 | 791 | 0.130 |
Why?
|
| Research Report | 1 | 2019 | 367 | 0.130 |
Why?
|
| Organization and Administration | 3 | 2014 | 54 | 0.130 |
Why?
|
| United States Food and Drug Administration | 4 | 2014 | 1662 | 0.130 |
Why?
|
| Equipment Safety | 1 | 2017 | 249 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 2478 | 0.130 |
Why?
|
| Disease Management | 5 | 2024 | 2507 | 0.130 |
Why?
|
| Ankle | 1 | 2019 | 350 | 0.130 |
Why?
|
| Case-Control Studies | 13 | 2016 | 22174 | 0.130 |
Why?
|
| Stents | 3 | 2010 | 3177 | 0.130 |
Why?
|
| Angioplasty | 3 | 2011 | 356 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2005 | 1212 | 0.130 |
Why?
|
| Tetrazoles | 4 | 2006 | 909 | 0.130 |
Why?
|
| Pneumonectomy | 1 | 2002 | 1118 | 0.130 |
Why?
|
| Myocardial Ischemia | 4 | 2019 | 2133 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 706 | 0.130 |
Why?
|
| Pulmonary Circulation | 5 | 1993 | 737 | 0.120 |
Why?
|
| Heart Atria | 5 | 2010 | 1349 | 0.120 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 588 | 0.120 |
Why?
|
| Foot | 1 | 2019 | 575 | 0.120 |
Why?
|
| Monitoring, Physiologic | 2 | 2000 | 1780 | 0.120 |
Why?
|
| Aortic Diseases | 1 | 2021 | 735 | 0.120 |
Why?
|
| Orthodontic Appliances, Removable | 1 | 2015 | 30 | 0.120 |
Why?
|
| Serum Albumin | 1 | 2018 | 674 | 0.120 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2019 | 1723 | 0.120 |
Why?
|
| Exercise Tolerance | 1 | 2020 | 838 | 0.120 |
Why?
|
| Epilepsy, Generalized | 1 | 1997 | 178 | 0.120 |
Why?
|
| Thallium | 3 | 1983 | 100 | 0.120 |
Why?
|
| Heart Arrest | 2 | 2005 | 1513 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 4 | 2004 | 2642 | 0.120 |
Why?
|
| Syndrome | 1 | 2021 | 3271 | 0.120 |
Why?
|
| Blood Platelets | 3 | 2014 | 2477 | 0.120 |
Why?
|
| Down Syndrome | 3 | 1988 | 901 | 0.120 |
Why?
|
| Emergency Medical Services | 2 | 2011 | 1920 | 0.120 |
Why?
|
| Advisory Committees | 2 | 2016 | 788 | 0.120 |
Why?
|
| Life Style | 3 | 2014 | 3907 | 0.120 |
Why?
|
| Diabetes Mellitus | 3 | 2023 | 5842 | 0.120 |
Why?
|
| Factor IX | 1 | 2014 | 76 | 0.120 |
Why?
|
| Quality of Health Care | 2 | 2009 | 4321 | 0.120 |
Why?
|
| Costs and Cost Analysis | 5 | 2009 | 1664 | 0.110 |
Why?
|
| Upper Extremity | 1 | 2019 | 658 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2019 | 3417 | 0.110 |
Why?
|
| Factor VII | 1 | 2014 | 139 | 0.110 |
Why?
|
| Fractures, Bone | 2 | 2023 | 2046 | 0.110 |
Why?
|
| Cross-Sectional Studies | 7 | 2020 | 26072 | 0.110 |
Why?
|
| Drug Approval | 3 | 2013 | 812 | 0.110 |
Why?
|
| Drug Utilization | 2 | 2019 | 1188 | 0.110 |
Why?
|
| Vascular Diseases | 3 | 2018 | 1160 | 0.110 |
Why?
|
| Drug Evaluation | 2 | 2014 | 641 | 0.110 |
Why?
|
| Hemostasis, Surgical | 1 | 1994 | 126 | 0.110 |
Why?
|
| Equipment Design | 3 | 2015 | 3510 | 0.110 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 134 | 0.110 |
Why?
|
| Snoring | 1 | 2015 | 209 | 0.110 |
Why?
|
| Endovascular Procedures | 2 | 2019 | 2181 | 0.110 |
Why?
|
| Oral Surgical Procedures | 1 | 2015 | 165 | 0.110 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 885 | 0.110 |
Why?
|
| Economics, Nursing | 1 | 2013 | 7 | 0.110 |
Why?
|
| Aorta | 1 | 2021 | 2040 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2004 | 1555 | 0.110 |
Why?
|
| Troponin I | 1 | 1997 | 652 | 0.110 |
Why?
|
| Radioisotopes | 3 | 1983 | 502 | 0.110 |
Why?
|
| Cost Savings | 3 | 2019 | 911 | 0.110 |
Why?
|
| Fluoroscopy | 1 | 2017 | 947 | 0.110 |
Why?
|
| Hypotension, Orthostatic | 1 | 2016 | 257 | 0.110 |
Why?
|
| Mortality | 4 | 2021 | 2896 | 0.100 |
Why?
|
| Platelet Activation | 1 | 1996 | 646 | 0.100 |
Why?
|
| Smoking | 9 | 2016 | 9055 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2017 | 454 | 0.100 |
Why?
|
| Vaccination | 2 | 2023 | 3369 | 0.100 |
Why?
|
| Seat Belts | 1 | 1992 | 60 | 0.100 |
Why?
|
| Ventilation-Perfusion Ratio | 4 | 2003 | 117 | 0.100 |
Why?
|
| Molecular Structure | 1 | 2016 | 1875 | 0.100 |
Why?
|
| Diabetes Complications | 2 | 2012 | 1316 | 0.100 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2010 | 1086 | 0.100 |
Why?
|
| Data Collection | 5 | 2014 | 3320 | 0.100 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 1390 | 0.100 |
Why?
|
| Conflict of Interest | 1 | 2017 | 554 | 0.100 |
Why?
|
| Blood Coagulation Factors | 1 | 2014 | 366 | 0.100 |
Why?
|
| Random Allocation | 8 | 1994 | 2393 | 0.100 |
Why?
|
| Creatinine | 2 | 2016 | 1897 | 0.100 |
Why?
|
| Hemoglobins | 1 | 2018 | 1525 | 0.100 |
Why?
|
| Methotrexate | 1 | 2018 | 1718 | 0.100 |
Why?
|
| Algorithms | 7 | 2023 | 14025 | 0.090 |
Why?
|
| Genotype | 7 | 2013 | 12985 | 0.090 |
Why?
|
| Risk Reduction Behavior | 2 | 2016 | 1111 | 0.090 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 3057 | 0.090 |
Why?
|
| Hip Fractures | 2 | 2023 | 989 | 0.090 |
Why?
|
| Knee Prosthesis | 1 | 1994 | 395 | 0.090 |
Why?
|
| Mass Screening | 3 | 2010 | 5426 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2016 | 1146 | 0.090 |
Why?
|
| Fee-for-Service Plans | 1 | 2016 | 698 | 0.090 |
Why?
|
| Cholesterol, HDL | 3 | 2011 | 1812 | 0.090 |
Why?
|
| Accidental Falls | 1 | 2019 | 1068 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2020 | 1589 | 0.090 |
Why?
|
| Hospitals, Urban | 2 | 2007 | 500 | 0.090 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2009 | 275 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2021 | 2598 | 0.090 |
Why?
|
| Dipyridamole | 1 | 2010 | 142 | 0.090 |
Why?
|
| Nursing Homes | 1 | 2018 | 1083 | 0.090 |
Why?
|
| Exercise | 4 | 2019 | 5874 | 0.090 |
Why?
|
| Hospitals, Community | 1 | 2013 | 365 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2017 | 3453 | 0.090 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2015 | 575 | 0.090 |
Why?
|
| Altitude Sickness | 1 | 2011 | 91 | 0.090 |
Why?
|
| Androgen Antagonists | 2 | 2010 | 1408 | 0.090 |
Why?
|
| Logistic Models | 7 | 2017 | 13249 | 0.090 |
Why?
|
| Laboratories, Hospital | 1 | 2011 | 192 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 1885 | 0.080 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2012 | 1221 | 0.080 |
Why?
|
| Brain Neoplasms | 2 | 2002 | 9025 | 0.080 |
Why?
|
| Water Pollution, Chemical | 1 | 1989 | 31 | 0.080 |
Why?
|
| Medication Therapy Management | 1 | 2010 | 130 | 0.080 |
Why?
|
| Television | 1 | 1992 | 407 | 0.080 |
Why?
|
| Cardiotonic Agents | 2 | 2019 | 540 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1992 | 488 | 0.080 |
Why?
|
| Pharmacogenetics | 3 | 2013 | 675 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2005 | 4788 | 0.080 |
Why?
|
| Food-Drug Interactions | 1 | 2009 | 24 | 0.080 |
Why?
|
| Personnel, Hospital | 1 | 2011 | 285 | 0.080 |
Why?
|
| Drug Dosage Calculations | 1 | 2009 | 117 | 0.080 |
Why?
|
| Ventricular Function, Left | 2 | 1993 | 3899 | 0.080 |
Why?
|
| Patient Care Team | 3 | 2013 | 2515 | 0.080 |
Why?
|
| Myocardium | 6 | 2002 | 4746 | 0.080 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2011 | 256 | 0.080 |
Why?
|
| Markov Chains | 3 | 2019 | 965 | 0.080 |
Why?
|
| Chromium | 1 | 1989 | 132 | 0.080 |
Why?
|
| Therapeutic Equivalency | 1 | 2009 | 134 | 0.080 |
Why?
|
| Ovary | 1 | 1993 | 957 | 0.080 |
Why?
|
| Pulmonary Gas Exchange | 3 | 2003 | 379 | 0.080 |
Why?
|
| Injections | 1 | 2012 | 832 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2011 | 590 | 0.080 |
Why?
|
| Home Care Services | 1 | 2015 | 647 | 0.080 |
Why?
|
| Joint Prosthesis | 1 | 1990 | 253 | 0.080 |
Why?
|
| Treatment Refusal | 1 | 2012 | 430 | 0.080 |
Why?
|
| Primary Prevention | 3 | 2017 | 1185 | 0.080 |
Why?
|
| Bed Rest | 1 | 2008 | 83 | 0.080 |
Why?
|
| Filtration | 1 | 1989 | 228 | 0.080 |
Why?
|
| Government | 1 | 2009 | 160 | 0.080 |
Why?
|
| Polysomnography | 1 | 2015 | 1848 | 0.080 |
Why?
|
| Coronary Angiography | 4 | 2007 | 4507 | 0.080 |
Why?
|
| Cardiac Output, Low | 2 | 2000 | 191 | 0.080 |
Why?
|
| Water Supply | 1 | 1989 | 204 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 3 | 2016 | 2465 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2016 | 5250 | 0.070 |
Why?
|
| Pressure | 3 | 1996 | 1155 | 0.070 |
Why?
|
| Hip Prosthesis | 1 | 1994 | 921 | 0.070 |
Why?
|
| Rheumatic Heart Disease | 1 | 2009 | 163 | 0.070 |
Why?
|
| Injections, Intravenous | 3 | 2008 | 1376 | 0.070 |
Why?
|
| Iodine Compounds | 1 | 2007 | 28 | 0.070 |
Why?
|
| Medical Record Linkage | 1 | 2009 | 286 | 0.070 |
Why?
|
| Carcinogens | 1 | 1989 | 452 | 0.070 |
Why?
|
| Nitroglycerin | 1 | 1988 | 330 | 0.070 |
Why?
|
| Blister | 1 | 2007 | 86 | 0.070 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2012 | 389 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2020 | 7965 | 0.070 |
Why?
|
| Food | 1 | 2011 | 768 | 0.070 |
Why?
|
| Chronic Disease | 4 | 2011 | 9319 | 0.070 |
Why?
|
| Death, Sudden | 3 | 2004 | 301 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2018 | 12159 | 0.070 |
Why?
|
| Blood Gas Analysis | 3 | 2004 | 379 | 0.070 |
Why?
|
| Alcohol Drinking | 4 | 2010 | 4027 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2016 | 5406 | 0.070 |
Why?
|
| Medical Audit | 1 | 2008 | 452 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 2194 | 0.070 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2010 | 774 | 0.070 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2007 | 187 | 0.070 |
Why?
|
| Fluid Therapy | 1 | 2010 | 578 | 0.070 |
Why?
|
| Duodenal Ulcer | 1 | 2006 | 121 | 0.070 |
Why?
|
| Laparotomy | 2 | 2007 | 456 | 0.060 |
Why?
|
| Estrogens | 2 | 2007 | 1522 | 0.060 |
Why?
|
| Vascular Resistance | 1 | 2009 | 933 | 0.060 |
Why?
|
| MEDLINE | 1 | 2005 | 119 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 4190 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 2 | 2007 | 1381 | 0.060 |
Why?
|
| Models, Theoretical | 2 | 2009 | 3571 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 1998 | 5333 | 0.060 |
Why?
|
| Splenectomy | 1 | 2007 | 391 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2007 | 426 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2015 | 2277 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 2 | 1994 | 3627 | 0.060 |
Why?
|
| Benzylamines | 1 | 2006 | 247 | 0.060 |
Why?
|
| Fetal Death | 1 | 2007 | 435 | 0.060 |
Why?
|
| Antiviral Agents | 3 | 2023 | 3048 | 0.060 |
Why?
|
| Azetidines | 1 | 2006 | 142 | 0.060 |
Why?
|
| Respiratory Insufficiency | 2 | 2011 | 1232 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 2009 | 601 | 0.060 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2019 | 1039 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 1520 | 0.060 |
Why?
|
| Hypertension, Renal | 1 | 2004 | 135 | 0.060 |
Why?
|
| Life Tables | 1 | 2004 | 364 | 0.060 |
Why?
|
| Myocardial Contraction | 3 | 2005 | 1516 | 0.060 |
Why?
|
| Antihypertensive Agents | 2 | 2005 | 2019 | 0.060 |
Why?
|
| Postpartum Period | 1 | 1991 | 1178 | 0.060 |
Why?
|
| Cardiomyopathies | 2 | 2019 | 2021 | 0.060 |
Why?
|
| Models, Cardiovascular | 3 | 2009 | 983 | 0.060 |
Why?
|
| Nursing Staff, Hospital | 1 | 2007 | 348 | 0.060 |
Why?
|
| Subtraction Technique | 2 | 2007 | 518 | 0.060 |
Why?
|
| Contrast Media | 4 | 2015 | 5311 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2017 | 6345 | 0.060 |
Why?
|
| Ultrasonography, Doppler | 2 | 2022 | 462 | 0.060 |
Why?
|
| Aerospace Medicine | 1 | 2004 | 95 | 0.060 |
Why?
|
| Animals | 10 | 2020 | 168089 | 0.060 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2007 | 495 | 0.050 |
Why?
|
| Cough | 1 | 2007 | 594 | 0.050 |
Why?
|
| Antibodies | 1 | 2011 | 2415 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2010 | 2114 | 0.050 |
Why?
|
| Endoscopy, Digestive System | 1 | 2006 | 353 | 0.050 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 431 | 0.050 |
Why?
|
| Angiotensinogen | 1 | 1984 | 160 | 0.050 |
Why?
|
| Walking | 1 | 2010 | 1194 | 0.050 |
Why?
|
| Angiotensins | 1 | 1984 | 141 | 0.050 |
Why?
|
| Gravity Suits | 1 | 2002 | 12 | 0.050 |
Why?
|
| Arginine | 1 | 2007 | 920 | 0.050 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2014 | 1535 | 0.050 |
Why?
|
| Resource Allocation | 1 | 1985 | 350 | 0.050 |
Why?
|
| Motor Activity | 2 | 2010 | 2712 | 0.050 |
Why?
|
| Nifedipine | 1 | 1983 | 220 | 0.050 |
Why?
|
| Drug Labeling | 1 | 2005 | 248 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2001 | 1208 | 0.050 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2005 | 583 | 0.050 |
Why?
|
| Oximetry | 1 | 2006 | 459 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 2756 | 0.050 |
Why?
|
| Decision Trees | 1 | 2004 | 505 | 0.050 |
Why?
|
| Employment | 1 | 2009 | 1114 | 0.050 |
Why?
|
| Human Rights | 1 | 1985 | 308 | 0.050 |
Why?
|
| Drugs, Generic | 1 | 2008 | 448 | 0.050 |
Why?
|
| Drug-Eluting Stents | 1 | 2008 | 681 | 0.050 |
Why?
|
| Specialization | 1 | 2007 | 778 | 0.050 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2005 | 732 | 0.050 |
Why?
|
| Pain | 2 | 2007 | 5072 | 0.050 |
Why?
|
| Hormones | 1 | 2006 | 868 | 0.050 |
Why?
|
| Diabetic Angiopathies | 2 | 2004 | 805 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 5145 | 0.050 |
Why?
|
| Sex Characteristics | 2 | 2023 | 2640 | 0.050 |
Why?
|
| Quality Control | 1 | 2005 | 833 | 0.050 |
Why?
|
| Lipid Regulating Agents | 1 | 2021 | 21 | 0.050 |
Why?
|
| Child | 7 | 2021 | 80154 | 0.050 |
Why?
|
| Inosine | 1 | 1982 | 129 | 0.050 |
Why?
|
| Renin | 1 | 1984 | 639 | 0.050 |
Why?
|
| Neutrophils | 1 | 2014 | 3763 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2015 | 3952 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2007 | 820 | 0.050 |
Why?
|
| Patient Admission | 2 | 2020 | 1365 | 0.050 |
Why?
|
| Pericarditis, Constrictive | 1 | 1981 | 46 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2015 | 3976 | 0.050 |
Why?
|
| Ventricular Dysfunction | 1 | 2002 | 144 | 0.050 |
Why?
|
| Stroke Volume | 3 | 2019 | 5521 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 989 | 0.050 |
Why?
|
| Poetry as Topic | 1 | 2000 | 17 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2020 | 8642 | 0.050 |
Why?
|
| Models, Economic | 2 | 2019 | 714 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 2 | 1999 | 1474 | 0.050 |
Why?
|
| Pregnancy Trimester, First | 1 | 2005 | 908 | 0.050 |
Why?
|
| Risk Management | 1 | 2004 | 557 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2005 | 1818 | 0.040 |
Why?
|
| Albuminuria | 1 | 2004 | 656 | 0.040 |
Why?
|
| Esters | 1 | 2021 | 210 | 0.040 |
Why?
|
| Cardiac Output | 1 | 1983 | 831 | 0.040 |
Why?
|
| Pelvic Bones | 1 | 2023 | 270 | 0.040 |
Why?
|
| Prejudice | 1 | 2005 | 572 | 0.040 |
Why?
|
| Epiglottitis | 1 | 2000 | 19 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 2006 | 1134 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2011 | 4052 | 0.040 |
Why?
|
| Radiographic Image Enhancement | 1 | 2005 | 877 | 0.040 |
Why?
|
| Aging | 2 | 2017 | 8702 | 0.040 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2001 | 190 | 0.040 |
Why?
|
| Thailand | 1 | 2021 | 287 | 0.040 |
Why?
|
| Internationality | 2 | 2017 | 999 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 1985 | 785 | 0.040 |
Why?
|
| Defibrillators, Implantable | 1 | 2010 | 1492 | 0.040 |
Why?
|
| Sulfhydryl Compounds | 1 | 2021 | 296 | 0.040 |
Why?
|
| Lung Diseases | 4 | 2005 | 1910 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 17897 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2011 | 8519 | 0.040 |
Why?
|
| Ankle Injuries | 1 | 2004 | 338 | 0.040 |
Why?
|
| Arteries | 2 | 2002 | 1121 | 0.040 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 578 | 0.040 |
Why?
|
| Taiwan | 1 | 2021 | 522 | 0.040 |
Why?
|
| Research Support as Topic | 2 | 1997 | 697 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2011 | 3183 | 0.040 |
Why?
|
| Cold Temperature | 1 | 1983 | 783 | 0.040 |
Why?
|
| Protein C | 2 | 1997 | 133 | 0.040 |
Why?
|
| Emergency Medicine | 1 | 1988 | 1198 | 0.040 |
Why?
|
| Preventive Medicine | 1 | 2001 | 245 | 0.040 |
Why?
|
| Fever | 1 | 2007 | 1618 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2019 | 6823 | 0.040 |
Why?
|
| Skull Base | 1 | 2022 | 292 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 1984 | 735 | 0.040 |
Why?
|
| Colectomy | 1 | 2004 | 686 | 0.040 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2002 | 451 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2002 | 1097 | 0.040 |
Why?
|
| Medicine | 1 | 2007 | 942 | 0.040 |
Why?
|
| Amides | 1 | 2021 | 449 | 0.040 |
Why?
|
| Aldosterone | 1 | 1984 | 869 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 1996 | 1436 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2021 | 576 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 2632 | 0.040 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2005 | 1191 | 0.040 |
Why?
|
| Long-Term Care | 2 | 2014 | 630 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2020 | 473 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2008 | 1796 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2023 | 708 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 1241 | 0.040 |
Why?
|
| Digoxin | 1 | 2019 | 246 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2009 | 1935 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2007 | 1399 | 0.040 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2019 | 152 | 0.040 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2017 | 29 | 0.040 |
Why?
|
| Acidosis, Respiratory | 1 | 1997 | 37 | 0.040 |
Why?
|
| alpha-2-Antiplasmin | 1 | 1997 | 13 | 0.040 |
Why?
|
| Melena | 1 | 1997 | 32 | 0.040 |
Why?
|
| Emotions | 1 | 2009 | 2742 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2006 | 1301 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 20982 | 0.040 |
Why?
|
| Hemostasis | 1 | 2020 | 470 | 0.040 |
Why?
|
| Extremities | 1 | 2023 | 867 | 0.040 |
Why?
|
| Antiplatyhelmintic Agents | 1 | 2016 | 2 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2023 | 915 | 0.040 |
Why?
|
| Demography | 1 | 2002 | 1641 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1977 | 0.030 |
Why?
|
| Angioplasty, Balloon | 1 | 2001 | 589 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 12676 | 0.030 |
Why?
|
| Health Policy | 1 | 2009 | 2679 | 0.030 |
Why?
|
| beta-Thromboglobulin | 1 | 1996 | 20 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 1983 | 1611 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2002 | 1092 | 0.030 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1996 | 80 | 0.030 |
Why?
|
| Hemiplegia | 1 | 1997 | 136 | 0.030 |
Why?
|
| Japan | 1 | 2021 | 1378 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2023 | 2082 | 0.030 |
Why?
|
| Patients | 1 | 2023 | 906 | 0.030 |
Why?
|
| Heart Rate | 3 | 2020 | 4197 | 0.030 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 1999 | 284 | 0.030 |
Why?
|
| Hospitals, Private | 1 | 1996 | 63 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 3885 | 0.030 |
Why?
|
| Mesothelioma | 1 | 2002 | 807 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2007 | 2631 | 0.030 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2020 | 702 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2004 | 991 | 0.030 |
Why?
|
| Spinal Fractures | 1 | 2023 | 704 | 0.030 |
Why?
|
| Endoscopes | 2 | 1974 | 169 | 0.030 |
Why?
|
| Hematuria | 1 | 1997 | 232 | 0.030 |
Why?
|
| Pneumonia | 2 | 2005 | 2142 | 0.030 |
Why?
|
| Hematocrit | 1 | 1997 | 623 | 0.030 |
Why?
|
| North America | 1 | 2019 | 1284 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 4107 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2000 | 890 | 0.030 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 3 | 1990 | 66 | 0.030 |
Why?
|
| Punctures | 1 | 2017 | 366 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1983 | 1490 | 0.030 |
Why?
|
| Information Systems | 1 | 1997 | 396 | 0.030 |
Why?
|
| Fiber Optic Technology | 2 | 1974 | 290 | 0.030 |
Why?
|
| DNA | 2 | 2014 | 7189 | 0.030 |
Why?
|
| Biological Availability | 1 | 1995 | 389 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 492 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2006 | 2092 | 0.030 |
Why?
|
| Infant | 3 | 2020 | 36170 | 0.030 |
Why?
|
| China | 1 | 2021 | 2374 | 0.030 |
Why?
|
| Thalidomide | 1 | 2020 | 885 | 0.030 |
Why?
|
| Half-Life | 1 | 1995 | 649 | 0.030 |
Why?
|
| Diastole | 1 | 1997 | 782 | 0.030 |
Why?
|
| Self Administration | 1 | 1996 | 387 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 6819 | 0.030 |
Why?
|
| Body Weight | 3 | 2015 | 4618 | 0.030 |
Why?
|
| World Health Organization | 1 | 2020 | 1321 | 0.030 |
Why?
|
| Laparoscopes | 1 | 1974 | 36 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2016 | 426 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2020 | 42225 | 0.030 |
Why?
|
| Electronic Health Records | 2 | 2023 | 4822 | 0.030 |
Why?
|
| Citrulline | 1 | 2014 | 107 | 0.030 |
Why?
|
| Protamines | 1 | 1994 | 112 | 0.030 |
Why?
|
| Linear Models | 2 | 2009 | 5869 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 961 | 0.030 |
Why?
|
| Diet | 1 | 2011 | 8048 | 0.030 |
Why?
|
| Cost Control | 1 | 1996 | 627 | 0.030 |
Why?
|
| Disease Progression | 3 | 2022 | 13511 | 0.030 |
Why?
|
| Death | 1 | 2018 | 677 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2006 | 3064 | 0.030 |
Why?
|
| Government Agencies | 2 | 1970 | 160 | 0.030 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1992 | 62 | 0.030 |
Why?
|
| Mutation | 4 | 2001 | 30004 | 0.030 |
Why?
|
| Placebos | 3 | 2006 | 1666 | 0.030 |
Why?
|
| Postoperative Care | 1 | 1999 | 1468 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 1002 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 1999 | 944 | 0.030 |
Why?
|
| Anaphylaxis | 1 | 2000 | 758 | 0.030 |
Why?
|
| Plasminogen Inactivators | 1 | 1992 | 37 | 0.030 |
Why?
|
| Technetium | 2 | 1983 | 326 | 0.030 |
Why?
|
| Italy | 1 | 1994 | 844 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 1504 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 2 | 1988 | 1123 | 0.030 |
Why?
|
| Apolipoprotein A-II | 1 | 1992 | 41 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2024 | 2150 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2004 | 1923 | 0.020 |
Why?
|
| Brain Ischemia | 2 | 1997 | 3032 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 1994 | 958 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 1983 | 410 | 0.020 |
Why?
|
| Autopsy | 2 | 1987 | 1010 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 2015 | 647 | 0.020 |
Why?
|
| Consciousness | 1 | 1997 | 601 | 0.020 |
Why?
|
| Physical Fitness | 1 | 1995 | 742 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6586 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 1996 | 1155 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2012 | 211 | 0.020 |
Why?
|
| Thorax | 1 | 1994 | 555 | 0.020 |
Why?
|
| Peroxidase | 1 | 2014 | 610 | 0.020 |
Why?
|
| Biological Warfare | 1 | 1970 | 24 | 0.020 |
Why?
|
| Chemical Warfare | 1 | 1970 | 18 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2002 | 13386 | 0.020 |
Why?
|
| Students, Health Occupations | 1 | 1970 | 29 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 1992 | 299 | 0.020 |
Why?
|
| Organ Culture Techniques | 2 | 1983 | 792 | 0.020 |
Why?
|
| France | 1 | 2011 | 492 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 1996 | 3577 | 0.020 |
Why?
|
| Heart Failure, Diastolic | 1 | 2011 | 77 | 0.020 |
Why?
|
| Heterozygote | 1 | 1997 | 2778 | 0.020 |
Why?
|
| Visual Fields | 1 | 1997 | 1061 | 0.020 |
Why?
|
| Gadolinium | 1 | 2015 | 961 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2014 | 1636 | 0.020 |
Why?
|
| Exercise Test | 2 | 2007 | 2165 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 1997 | 1141 | 0.020 |
Why?
|
| Microvessels | 1 | 2014 | 580 | 0.020 |
Why?
|
| Nomograms | 1 | 2011 | 230 | 0.020 |
Why?
|
| Vision Disorders | 1 | 1997 | 1089 | 0.020 |
Why?
|
| Statistics as Topic | 3 | 2009 | 2359 | 0.020 |
Why?
|
| Heart Failure, Systolic | 1 | 2011 | 135 | 0.020 |
Why?
|
| Prostatectomy | 1 | 1997 | 1825 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 14610 | 0.020 |
Why?
|
| Professional Practice | 1 | 2011 | 313 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2006 | 5092 | 0.020 |
Why?
|
| United States Environmental Protection Agency | 1 | 1989 | 139 | 0.020 |
Why?
|
| Vena Cava, Superior | 1 | 2010 | 196 | 0.020 |
Why?
|
| Health Planning | 1 | 1970 | 231 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2018 | 3210 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 942 | 0.020 |
Why?
|
| Amiodarone | 1 | 2010 | 217 | 0.020 |
Why?
|
| Saphenous Vein | 1 | 1991 | 516 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 1990 | 411 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2014 | 2048 | 0.020 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 1977 | 1492 | 0.020 |
Why?
|
| Clothing | 1 | 1988 | 96 | 0.020 |
Why?
|
| Activated Protein C Resistance | 1 | 2007 | 18 | 0.020 |
Why?
|
| Heart Auscultation | 1 | 1987 | 33 | 0.020 |
Why?
|
| Abdomen | 1 | 1974 | 1128 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 1784 | 0.020 |
Why?
|
| Asphyxia Neonatorum | 1 | 1988 | 111 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 2643 | 0.020 |
Why?
|
| Carotenoids | 1 | 1990 | 621 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 1997 | 2725 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 1624 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 2635 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 6067 | 0.020 |
Why?
|
| Sodium Pertechnetate Tc 99m | 2 | 1983 | 54 | 0.020 |
Why?
|
| Financing, Government | 1 | 1970 | 472 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 1996 | 2420 | 0.020 |
Why?
|
| Internet | 1 | 1998 | 3096 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2007 | 276 | 0.020 |
Why?
|
| Beer | 1 | 1986 | 134 | 0.020 |
Why?
|
| American Heart Association | 1 | 2011 | 1043 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2007 | 216 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 1988 | 713 | 0.020 |
Why?
|
| Fibrin | 1 | 1988 | 507 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2013 | 1242 | 0.020 |
Why?
|
| Heart Murmurs | 1 | 1986 | 92 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 1986 | 384 | 0.020 |
Why?
|
| Colon | 1 | 1974 | 1791 | 0.020 |
Why?
|
| Systems Integration | 1 | 2007 | 428 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7804 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 1130 | 0.020 |
Why?
|
| Institutionalization | 1 | 1986 | 106 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2020 | 26200 | 0.020 |
Why?
|
| Metoprolol | 1 | 2005 | 90 | 0.020 |
Why?
|
| Community Health Services | 1 | 1970 | 655 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2007 | 514 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2005 | 372 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2005 | 5885 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1996 | 4420 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 3512 | 0.010 |
Why?
|
| Carbon Disulfide | 1 | 1983 | 5 | 0.010 |
Why?
|
| Hydrocarbons, Halogenated | 1 | 1983 | 20 | 0.010 |
Why?
|
| Education, Medical, Undergraduate | 1 | 1973 | 1072 | 0.010 |
Why?
|
| Decision Making | 2 | 1995 | 3931 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1990 | 1111 | 0.010 |
Why?
|
| Noise, Occupational | 1 | 1983 | 26 | 0.010 |
Why?
|
| Surgical Equipment | 1 | 1984 | 57 | 0.010 |
Why?
|
| Factor VIII | 1 | 2006 | 349 | 0.010 |
Why?
|
| Histones | 1 | 2014 | 2570 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 15920 | 0.010 |
Why?
|
| Adolescent Behavior | 1 | 1992 | 1188 | 0.010 |
Why?
|
| Ileostomy | 1 | 2004 | 121 | 0.010 |
Why?
|
| Carbon Monoxide Poisoning | 1 | 1983 | 65 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9278 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2015 | 1847 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2005 | 36415 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2008 | 1391 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 18222 | 0.010 |
Why?
|
| Counterimmunoelectrophoresis | 1 | 1982 | 14 | 0.010 |
Why?
|
| Amlodipine | 1 | 2003 | 84 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2010 | 1223 | 0.010 |
Why?
|
| Case Management | 1 | 2004 | 272 | 0.010 |
Why?
|
| beta Carotene | 2 | 1997 | 523 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2425 | 0.010 |
Why?
|
| Cardiomegaly | 2 | 2000 | 590 | 0.010 |
Why?
|
| Intestinal Perforation | 1 | 2004 | 249 | 0.010 |
Why?
|
| Diphosphates | 1 | 1982 | 89 | 0.010 |
Why?
|
| Exercise Therapy | 1 | 1989 | 922 | 0.010 |
Why?
|
| Nitrates | 1 | 1983 | 260 | 0.010 |
Why?
|
| Trace Elements | 1 | 1983 | 193 | 0.010 |
Why?
|
| Radiology | 1 | 2016 | 2112 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1983 | 2087 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2010 | 1962 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2011 | 3430 | 0.010 |
Why?
|
| Varicose Veins | 1 | 1983 | 156 | 0.010 |
Why?
|
| Internal Medicine | 1 | 1988 | 1050 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2005 | 898 | 0.010 |
Why?
|
| Surgical Mesh | 1 | 1984 | 311 | 0.010 |
Why?
|
| Thinness | 1 | 2004 | 481 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1987 | 943 | 0.010 |
Why?
|
| Fetal Heart | 1 | 1982 | 281 | 0.010 |
Why?
|
| Forecasting | 1 | 1990 | 2928 | 0.010 |
Why?
|
| Education, Medical | 1 | 1972 | 1725 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 11067 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 17598 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 1991 | 2923 | 0.010 |
Why?
|
| Computers | 1 | 1983 | 591 | 0.010 |
Why?
|
| Cholesterol | 2 | 1993 | 2902 | 0.010 |
Why?
|
| Angiotensin II | 1 | 2003 | 848 | 0.010 |
Why?
|
| Family Health | 1 | 2005 | 1254 | 0.010 |
Why?
|
| Curriculum | 1 | 1973 | 3741 | 0.010 |
Why?
|
| Mitral Valve | 1 | 1988 | 1465 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 691 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2004 | 1963 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 2827 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2000 | 318 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 2000 | 527 | 0.010 |
Why?
|
| Aortic Valve | 1 | 1988 | 1959 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1992 | 3200 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 1791 | 0.010 |
Why?
|
| Pulmonary Edema | 1 | 2001 | 408 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 2000 | 436 | 0.010 |
Why?
|
| Diuretics | 1 | 2001 | 611 | 0.010 |
Why?
|
| Fibrinolysin | 1 | 1997 | 130 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1983 | 1434 | 0.010 |
Why?
|
| Antithrombin III | 1 | 1997 | 128 | 0.010 |
Why?
|
| Sterilization, Tubal | 2 | 1974 | 75 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1983 | 1867 | 0.010 |
Why?
|
| Vascular Patency | 1 | 2000 | 911 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1983 | 1191 | 0.010 |
Why?
|
| Colitis | 1 | 2004 | 1234 | 0.010 |
Why?
|
| Fetus | 1 | 1983 | 1864 | 0.010 |
Why?
|
| Creatine Kinase | 2 | 1991 | 684 | 0.010 |
Why?
|
| Coronary Vessels | 2 | 1985 | 3111 | 0.010 |
Why?
|
| Insulin | 1 | 2010 | 6588 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 1997 | 616 | 0.010 |
Why?
|
| Hysterectomy | 1 | 1999 | 857 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1985 | 398 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 2691 | 0.010 |
Why?
|
| Health Surveys | 1 | 1984 | 4037 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 1994 | 320 | 0.010 |
Why?
|
| Cholesterol, LDL | 2 | 1993 | 2380 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 9458 | 0.010 |
Why?
|
| Students, Premedical | 1 | 1972 | 3 | 0.010 |
Why?
|
| Polyps | 1 | 1974 | 200 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 16575 | 0.010 |
Why?
|
| Apolipoproteins | 1 | 1993 | 327 | 0.010 |
Why?
|
| Heart Neoplasms | 1 | 1995 | 364 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1988 | 9187 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1996 | 1147 | 0.010 |
Why?
|
| Tear Gases | 1 | 1970 | 5 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1995 | 877 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 1990 | 143 | 0.010 |
Why?
|
| Chemical Warfare Agents | 1 | 1970 | 19 | 0.010 |
Why?
|
| Tennessee | 1 | 1970 | 119 | 0.010 |
Why?
|
| Medical Records | 1 | 1996 | 1409 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1995 | 1838 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 1992 | 385 | 0.010 |
Why?
|
| Herbicides | 1 | 1970 | 105 | 0.010 |
Why?
|
| Vietnam | 1 | 1970 | 406 | 0.010 |
Why?
|
| Plethysmography, Impedance | 1 | 1988 | 42 | 0.000 |
Why?
|
| Blood Glucose | 1 | 1983 | 6392 | 0.000 |
Why?
|
| Morbidity | 1 | 1974 | 1751 | 0.000 |
Why?
|
| Stress, Psychological | 1 | 1983 | 4487 | 0.000 |
Why?
|
| Postmenopause | 1 | 1996 | 2514 | 0.000 |
Why?
|
| Schools, Medical | 1 | 1973 | 878 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1991 | 1682 | 0.000 |
Why?
|
| Rats | 1 | 1983 | 23705 | 0.000 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1970 | 793 | 0.000 |
Why?
|
| Apolipoproteins E | 1 | 1992 | 1443 | 0.000 |
Why?
|
| Triglycerides | 1 | 1993 | 2457 | 0.000 |
Why?
|
| Mice | 2 | 1983 | 81330 | 0.000 |
Why?
|
| Educational Measurement | 1 | 1972 | 1250 | 0.000 |
Why?
|
| Universities | 1 | 1970 | 995 | 0.000 |
Why?
|
| Energy Metabolism | 1 | 1995 | 2877 | 0.000 |
Why?
|
| Oxygen | 1 | 1996 | 4228 | 0.000 |
Why?
|
| Endoscopy | 1 | 1974 | 1852 | 0.000 |
Why?
|
| Coronary Care Units | 1 | 1985 | 235 | 0.000 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 1982 | 50 | 0.000 |
Why?
|
| Laparoscopy | 1 | 1974 | 2035 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1974 | 2527 | 0.000 |
Why?
|
| Research | 1 | 1970 | 1976 | 0.000 |
Why?
|
| Polymers | 1 | 1987 | 1617 | 0.000 |
Why?
|
| Heart Defects, Congenital | 1 | 1996 | 4673 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1996 | 8998 | 0.000 |
Why?
|
| Mental Health Services | 1 | 1970 | 1716 | 0.000 |
Why?
|
| Particle Size | 1 | 1982 | 1649 | 0.000 |
Why?
|
| Students, Medical | 1 | 1970 | 1940 | 0.000 |
Why?
|
| Health Services Accessibility | 1 | 1992 | 5426 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1982 | 2413 | 0.000 |
Why?
|
| Intestinal Polyps | 1 | 1973 | 105 | 0.000 |
Why?
|
| Methods | 1 | 1973 | 1063 | 0.000 |
Why?
|